曲马多作为芬太尼掺杂物:ToxIC Fentalog 研究前瞻性队列中的患病率与管理
该多中心前瞻性队列纳入8家美国急诊科疑似阿片类过量的成人患者,血清经液相色谱四极杆飞行时间质谱检测阿片类、新型精神活性物质及掺杂物,比较检出与未检出曲马多两组在纳洛酮使用、插管、CPR或死亡上的差异。2020年9月21日至2021年10月31日筛查2298例,537例符合纳入标准,81例(15%)曲马多检测阳性。两组慢性处方阿片使用(p=0.81)、慢性疼痛(p=0.27)、接受单次/第二次/第三次纳洛酮剂量的人数(p=0.25;0.92;0.59)、启动纳洛酮输注的比例(p=0.84)以及插管、CPR、死亡结局(p=0.26;0.75;0.29)均无显著差异。结论提示非法制造的芬太尼中可能掺有曲马多,但其存在与治疗无反应、过量严重程度差异或并发症风险增加无关。
要点
- 8家美国急诊科疑似阿片类过量成人中,81/537例(15%)血清检出曲马多,提示非法芬太尼掺假。
- 曲马多检出组与未检出组接受单次、第二次、第三次纳洛酮剂量的人数无显著差异(p=0.25;0.92;0.59)。
- 两组启动纳洛酮输注的比例无显著差异(p=0.84)。
- 两组插管、CPR、死亡结局均无显著差异(p=0.26;0.75;0.29)。
- 曲马多检出与慢性处方阿片使用(p=0.81)或慢性疼痛(p=0.27)无显著差异。
适用人群与场景
- 8家美国急诊科就诊的疑似阿片类过量成人患者,纳入Toxicology Investigators Consortium的Fentalog研究。
研究设计与关键结果
- 多中心前瞻性队列:2020年9月21日至2021年10月31日筛查2298例,537例符合纳入标准,81例(15%)血清曲马多检测阳性。
- 曲马多检出组与未检出组在慢性处方阿片使用(p=0.81)和慢性疼痛(p=0.27)上无显著差异。
- 两组接受单次、第二次、第三次纳洛酮剂量的人数无显著差异(p=0.25;0.92;0.59),启动纳洛酮输注的比例无显著差异(p=0.84)。
- 两组插管、CPR、死亡结局无显著差异(p=0.26;0.75;0.29)。
证据类型、等级与局限
- 证据类型:多中心前瞻性队列研究(ToxIC Fentalog研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 疑似阿片类过量患者中检出曲马多掺假并不提示治疗反应差、过量严重程度更高或并发症风险增加(原文结论)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Tramadol is an adulterant of illicit opioids. As it is a serotonin-norepinephrine reuptake inhibitor as well as a μ-opioid agonist, tramadol adulteration may worsen overdose signs and symptoms or affect the amount of naloxone patients receive.
METHODS: This is a multicenter, prospective cohort of adult patients with suspected opioid overdoses who presented to one of eight United States emergency departments and were included in the Toxicology Investigators Consortium's Fentalog Study. Patient serum was analyzed via liquid chromatography quadrupole time-of-flight mass spectroscopy to detect opioids, novel psychoactive substances, and adulterants. Patients were separated into groups of those with tramadol detected versus no tramadol detected. Differences in naloxone administration, intubation, performance of cardiopulmonary resuscitation (CPR), or death between those exposed or not exposed to tramadol were evaluated.
RESULTS: From September 21, 2020 - October 31, 2021; 2298 patients were screened and 537 met inclusion criteria. Eighty-one patients (15 %) tested positive for tramadol. There was no significant difference found between those who reported chronic prescription opioid use (p = 0.81) or reported chronic pain (p = 0.27). Additionally, no difference was found between groups in the number of patients receiving a single, second, or third dose of naloxone (p = 0.25; 0.92; 0.59) or the proportion initiated on a naloxone infusion (p = 0.84). Similarly, there was no difference in outcomes of intubation, CPR, or death (p = 0.26; 0.75; 0.29).
CONCLUSIONS: Tramadol was identified in a subset of patients presenting to the Emergency Department with opioid overdoses suggesting adulteration of illicitly manufactured fentanyl with tramadol. Its presence was not associated with a lack of treatment response, difference in severity of overdose, or increased risk of complications.
参考来源
- Dicker F, Lothet E, Schwarz E, et al. Tramadol as a fentanyl adulterant: Prevalence and management in a ToxIC Fentalog study prospective cohort. Am J Emerg Med. 2024. PMID: 39729684. doi:10.1016/j.ajem.2024.12.038
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。